Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Long-term recurrence-free and distant metastasis-free survival favours adjuvant nivolumab over ipilimumab
Systemic treatment based on molecular analysis did not improve survival over empiric chemotherapy in patients with carcinomas of unknown primary site
Two exploratory analysis of the relationship between tissue tumour mutational burden and pembrolizumab efficacy provided conflicting findings
Presentations cover a new classification strategy that may be prognostic of outcome and a new treatment option for leptomeningeal metastases in NSCLC patients
Lung cancer and other thoracic tumours; Anticancer agents and biologic therapy; Personalised medicine
More patients were able to undergo resection following induction chemotherapy
Nivolumab improved response and showed trend towards improved survival compared to sorafenib in the first-line setting in patients with advanced hepatocellular carcinoma
Arsenic trioxide Accord is intended for the treatment of acute promyelocytic leukaemia
Bortezomib Fresenius Kabi is intended for the treatment of multiple myeloma and mantle cell lymphoma
New indication concerns combination with axitinib for the first-line treatment of adults with advanced RCC
It is indicated for the treatment of adult patients who have relapsed or refractory AML with a FLT3 mutation
Evidence for efficacy is based on the results from the TITAN trial
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
